Thursday, 13 Dec 2018

In Argentina, cancer mortality in men it dropped 5%

The figures correspond to the period 2011-2015 compared to 2007-2011.

Medical advances In Argentina, cancer mortality in men decreased by 5%. The figures correspond to the period 2011-2015 compared to 2007-2011. The figures correspond to the period 2011-2015 compared to 2007-2011.

The Litoral |

Cancer mortality in men decreased by 5% in Argentina between 2011 and 2015 with respect to the period 2007-2011, reported the National Cancer Institute (INC), which highlighted “the creation of control and prevention programs, awareness and reduction of smoking habit “as the main causes of the decrease.

Thus, according to the new edition of the Cancer Mortality Atlas published by the INC, the age-adjusted rate (Tae) records similar values ​​in both periods for women (88 per 100,000), while in men it decreases by 131.5. to 124.9 per 100,000 (5%).

“It is a global decline in mortality for all tumors, but there is a strong impact on cancers of the lung and prostate, which until 2015 had been falling at a rate of almost 2% annually in both cases, and colorectal, which is somewhat stagnated but also went down, “he told Télam Graciela Abriata, coordinator of the Epidemiological Surveillance System and Cancer Report (Siver-Ca).

Also, according to the report, the highest number of deaths from cancer still corresponds in men to those tumors (lung, prostate and colon-rectum), while women die more from breast, lung and colon-rectum cancer.

The second indicator to consider is that of potential years of life lost (YPLL), which measures the impact of premature death due to the disease, that is, those deaths that occurred before people reached 80 years of age, life expectancy average of the country.

“When the YPLL are observed, tumors that determine not only a greater number of deaths, but also record a high mortality rate at younger ages become important,” Abriata said.

The gynecologist and epidemiologist said that “since the creation of the INC in 2011 and thanks to the generation of control and prevention programs and awareness work to reduce risk factors, especially the smoking habit, there was a strong impact on the low of the mortality rate in all the provinces. ”

“Less than 10 years ago, cancer was not a frequent issue on the agenda of our health ministers, and the creation of INC changed history. There were advances in early detection, promotion and prevention of the disease, which added to the technological advances helped to achieve this achievement, “the official completed.

The report also shows that the highest values ​​of YPLL in women are observed in the northeastern region of the country, and in men in the provinces of Formosa, Entre Ríos, La Pampa and Chubut.

On the other hand, high rates of mortality from colorectal cancer in both sexes were observed in Entre Rios, Santa Fe, Santa Cruz, Tierra del Fuego and La Pampa, provinces that, like the City of Buenos Aires, also share the highest mortality. elevated due to lung cancer in men and women.

“The knowledge of the distribution of cancer mortality in absolute numbers and the burden of disease they represent, will make it possible to better direct and focus the efforts of government agencies in terms of prevention, early diagnosis and treatment of cancer,” he said. prolog of the publication the former director of the INC, Roberto Pradier, who died this year.

“We are hopeful that information will be a valuable tool to reduce inequalities and improve cancer control in our country,” he added.

According to data from the 2011-2015 period, cancer represents approximately 20% of the mortality in Argentina, with more than 60,000 deaths per year.

New therapy for the lung

A new treatment for lung cancer that combines chemotherapy and immunotherapy and reduces the risk of death by 51% is already available in Argentina, experts said.

This is the immuno-oncological drug pembrolizumab for combined use with chemotherapy containing pemetrexed and carboplatin (carbo / pem), which was recently approved by Anmat as a first-line treatment in patients with non-small cell lung cancer (Cpcnp) , which represents between 85 and 90% of cases.

An international study published this week in “The New England Journal of Medicine” showed that this combination “reduces the risk of death by 51% -compared with chemotherapy alone- to treat non-squamous metastatic Cpcnp.”

“In the study, conducted in 616 treatment-naïve patients, all the objectives sought were achieved: better response rate, progression-free survival and increased overall survival,” Claudia Bagnes, Head of Oncology at Hospital Tornú, told Télam.

The specialist stressed that the results obtained “are highly rewarding.”

“The benefit of adding pembrolizumab to chemotherapy was demonstrated in all groups of patients,” he said.

On the other hand, Leena Gandhi, of the Thoracic Clinical Oncology Section at the NYU Langone’s Perlmutter Cancer Center in New York and first author of the published article, agreed, adding that “the clinical data found suggest that combination as a new standard of treatment first line for the disease. ”

“Our goal is to prolong the lives of patients with lung cancer, and the study’s survival findings, which show that the risk of death was reduced by 51%, are also important for the medical community,” Roger said. Perlmutter, president of Merck Research Laboratories.

Lung cancer is one of the most lethal, especially if diagnosed late, and is the most common malignant tumor worldwide.

The most common symptoms are respiratory distress, cough (sometimes accompanied by bloody expectoration) and weight loss, as well as chest pain and hoarseness.

According to the International Agency for Research on Cancer, of the World Health Organization (WHO), it is the third most prevalent in Argentina, with 11,242 new cases per year, but mortality is higher than that of breast cancer or the colorectal, with 10,531 deaths per year.

In addition, it is in first place for males (7,422 annual deaths) and in third place for women (3,109 annual deaths).

%d bloggers like this: